#60. Cracking the "Undruggable" Target
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
#60. Cracking the "Undruggable" Target
-
Narrated by:
-
By:
Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targeted therapy nearly doubled overall survival for metastatic pancreatic cancer patients compared to standard chemotherapy, extending it to 13.2 months. Join us as we explore the structural biology behind this tri-complex inhibitor, its unique resistance profile, and the future of precision cancer therapy. Produced by Dr. Jake Chen.
adbl_web_anon_alc_button_suppression_t1
No reviews yet